Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Corporate Update (November 2017)

14 slides from Windtree Therapeutics's corporate update, Nov 1, 2017

  1. Slide 1: Investor Conference Call: Financial Restructuring Initiative and Transactions

    Se we WINDTREE Investor Conference Call Financial Restructuring Initiative and Transactions November 2, 2017 OTCQB:WINT

  2. Slide 2: Forward-looking Statement

    Forward-looking Statement To the extent that statements in this presentation are not strictly historical, including statements about the Company’s clinical development programs, business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agreem

  3. Slide 3: Successfully Completed Financial Restructuring Program

    Successfully Completed Financial Restructuring Program = Closed $10 million Share Purchase Agreement resulting in Lee’s Pharm obtaining a controlling interest in Windtree = Windtree and Deerfield restructured and retired $25 million long- term debt = Windtree and Battelle Memorial Institute have sig

  4. Slide 4: Rationale for Transactions

    Rationale for Transactions = Our KL4 platform assets — beginning with AEROSURF® for the treatment of respiratory distress syndrome (RDS) in premature infants — represent a significant opportunity. However, significant additional investment is required to advance and realize the full potential of the

  5. Slide 5: Strategy

    Strategy Execute a broad financial restructuring initiative via a strategic transaction that would: 1. Rapidly secure the cash needed to fund operations with a focus on maintaining our assets and advancing the AEROSURF® program 2. Remove the financial overhang caused by long-term debt; address the b

  6. Slide 6: Elements of the Transactions: Lee's Share Purchase

    se §G Elements of the Transactions 1 Lee’s Share Purchase * To fund a cash resource gap, Lee’s entered into the previously announced August 2017 Loan Agreement and advanced Windtree $3.9 million * Lee’s purchased $10 million of common stock at approximately $0.22 per share —$6.1 million cash receive

  7. Slide 7: Elements of the Transactions (cont'd): Deerfield Debt Retirement

    Elements of the Transactions (cont’d) 2 Deerfield Debt Retirement * Deerfield agreed to restructure and retire its $25 million secured loan to facilitate the Lee’s share purchase. In exchange for the retirement of debt, Deerfield received: —$2.5 million of share purchase proceeds — 1.4 million share

  8. Slide 8: Results and Benefits of the Restructuring Initiative

    Results and Benefits of the Restructuring Initiative f Significantly improved capital structure by removing-the financial overhang of long-term debt WA Lowered the ongoing, non-program related cash burn rate through a combination of a 40% headcount reduction and other cost cutting measures S Better

  9. Slide 9: Lee's Pharm Overview

    Lee’s Pharm Overview = Hong Kong based and listed, research and development focused biopharmaceutical company = Founded in 1994 with over HKS900MM in net revenues in 2016 = Business anchored in proprietary drug development with a BD focus on late stage co-development and mature product registrations

  10. Slide 10: Rationale and Intent for Lee's

    Rationale and Intent for Lee’s Lee’s stated rationale for the deal and intent: 1. High belief in the assets and program * Dr Li has followed Windtree for some time and is compelled by the synthetic surfactant platform (both aerosolized and non-aerosolized in RDS as well as other potential indication

  11. Slide 11: Financial Update

    Financial Update * Cash and cash equivalents of $5.4 million as of November 1, 2017 — The Company anticipates that currently existing cash will be sufficient to fund operations into January 2018 while we seek to secure the additional capital required to satisfy existing obligations and fund our oper

  12. Slide 12: Focused on Our Key Objectives

    Focused on Our Key Objectives extremely consistent, high performing Phase 3 / “go to market” drug delivery platform Complete Device Development delivering an C= Solid execution in the clinic with the e Bridge / Confirm Study FDA AEROSURF and LS Global Regulatory 9° Clarity and employed in developmen

  13. Slide 13: Value Creating Potential

    2 Value Creating Potential Sy we WINDTREE THERAPEUTICS = Potentially transformative therapy addressing both the unmet efficacy and safety needs in the important, acute neonatology market = Multiple phase 2 clinical trials producing and replicating efficacy while continuing to build safety and tolera

  14. Slide 14: Windtree Therapeutics

    Windtree Therapeuti

Windtree Therapeutics — Corporate Update (November 2017) on 6ix